Pipeline

Galileo is a robust anti-generating platform that develops the most innovative and cutting edge types of monoclonal antibodies.

The Company has one of the most extensive and diversified portfolios in the sector to tackle an array of oncological disorders.

Commitment

At the core of Galileo’ commitment to developing transformative medicines for patients in need is the powerful combination of innovative antibody development strategies, creative science, passionate people, and cutting-edge technologies. The use of antibodies to harness and unleash the full power of the immune system holds unparalleled potential to treat a wide array of medical conditions for which there are currently no satisfactory treatment alternatives. We trust antibody therapeutics hold tomorrow’s breakthroughs in healthcare.